Clinical Trial Update: Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Avitene and OK-432 to reduce seroma formation after axillary lymphadenectomy in breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Avitene (Microfibrillar collagen hemostat)
• OK-432 (Streptococcal pyrogenic exotoxin-based immunotherapy (picibanil))

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Drainage, Postoperative Complications | Phase 4 | Status: UNKNOWN